Figure 1. Pseudotyping of Rhabdoviral Vectors with Human Coreceptors
In the top left, HIV-1 infects a cell using the viral proteins gp120 and gp41 (both in red, shown as a monomer) by binding via a coreceptor complex of CD4 and a chemokine receptor (both colored in blue). Binding activates fusion of the virus with the cell, resulting in infection. In the right bottom, an engineered Rhabdovirus binds to an HIV-1-infected cell by incorporation of the same coreceptor complex (blue) into the Rhabdoviral envelope. Binding to gp120/gp41 also initiates fusion, but this time allowing the engineered virus access to the HIV-1 infected cell, resulting in infection by the Rhabdovirus and death of the cell. called gp41, to activate a rod-like "fusion domain" strucother than that of HIV-1 to initiate a membrane fusion event. ture that pierces the membrane of the target cell and allows the viral membrane to fuse with the cell mem-
The approaches detailed by the Yale and Tü bingen groups (Schnell et al., 1997; Mebatsion et al., 1997) took brane (Chan et al., 1997; Weissenhorn et al., 1997) . By this action HIV-1 breaches the cell's primary wall of this understanding to a directed conclusion by replacing the normal viral envelope protein of certain Rhabdovidefense and injects its core proteins and genetic information into the cell. From here, reverse transcription, ruses with a human coreceptor complex, in this case CD4 and the chemokine receptor CXCR4. Incorporation viral integration, and HIV-1 gene expression can commence and viral replication can ensue.
of these proteins into the membrane of an engineered Rhabdovirus now compelled its binding to, and infection New understandings of the coreceptor complex to which HIV-1 binds on human cells is the essence that of, only those cells expressing HIV-1 gp120 and gp41. In essence, the coreceptor complex in the engineered drives the experiments in the current reports. Each coreceptor complex has one constant protein, the surface virus membrane is used as bait for gp120/gp41. Those cells about to release new HIV-1 virions, which are by glycoprotein CD4, and one "variable" component, called a chemokine receptor. As the constant member of the necessity expressing gp120/gp41, take the bait by binding the coreceptors embedded in the engineered virus coreceptor complex, CD4 has been long-known as a primary binding target of the HIV-1 gp120 envelope promembranes and fuse with them. Thus, the hunter-seeker virus enters the cell, whereupon it replicates within it tein. CD4 is expressed on certain subclasses of T cells and macrophages, acting as the common anchor for and can be caused to destroy that cell alone. The difficult part of the experiment was coaxing the gp120 recognition of target cells. The variable component is drawn from a family of proteins termed "chemoRhabdovirus to incorporate sufficient levels of the coreceptors to initiate binding to target cells expressing kine receptors." The specificity of different HIV-1 isolates to preferentially replicate within primary CD4 ϩ T gp120/gp41. The Yale and Tü bingen (Schnell et al., 1997; Mebatsion et al., 1997 ) groups went about this in differcells (so-called T-tropic strains of HIV-1), or primary macrophages and CD4 ϩ T cells (M-tropic HIV-1 strains), ent ways based upon significant historical perspectives. Varmus and colleagues had previously shown that CD4 or other cell types is determined by regions of the viral envelope that can specifically bind one "variable comcould be incorporated into the membranes of a retrovirus called avian leukosis virus and had proposed that ponent" chemokine receptor but not another (Moore, 1997; Broder and Collman, 1997) . Strains of HIV-1 having this might be a technique by which one could deliver genes specifically to HIV-1-infected cells (Young et al., T-tropic envelope proteins use CD4 plus the chemokine receptor CXCR4 (expressed primarily on T cells), whereas 1990). Although the role of the chemokine receptors had not been fully appreciated at the time, those earlier M-tropic envelope proteins use CD4 along with the chemokine receptor called CCR5 (expressed mainly on experiments, along with the results of many others, showed that viruses were not always selective in what macrophages and T cells, see Moore, 1997; Broder and Collman, 1997) . Other strains of HIV-1 have more flexible they allowed to mingle with their own envelope proteins in the lipid bilayer of their membranes. cellular host ranges and use CD4 plus chemokine receptors such as CCR2b or CCR3. The normal function of Given this, the Tü bingen group (Mebatsion et al., 1997 ) set about an approach in which they created cells that chemokine receptors in the body is to respond to the binding of specialized small soluble proteins, termed expressed high levels of a coreceptor protein pair, in this case CXCR4 chemokine receptor and CD4. Then, chemokines, by inducing immune system cells to mobilize toward the source of the chemokine (Murphy, 1996) . they introduced into these cells a Rhabdovirus (in this case a Rabies virus) that had been made defective by With these elements of the mechanism understood, and with newly enabled techniques to engineer, at the deletion of its own envelope protein (termed the G protein). As wild-type Rhabdoviral replication proceeds, molecular level, the genome and envelope constituents of another virus group, namely the Rhabdoviridae (Concompleting in as little as 4 hr and killing the cell, it culminates with its nucleoprotein core budding from the zelmann, 1996), the stage is set for specific targeting of HIV-1-infected cells by engineered delivery devices.
cell, carrying with it cellular membrane material as a protective sheath. In that membrane is the viral G proSwitch and Bait: Coreceptor Complexes in Viral Membranes Allow Engineered Cell tein, concentrated by its association with Rhabdoviral core proteins during Rhabdoviral assembly, as well as Entry via HIV-1 gp120/gp41 From a physical point of view, the process of fusion of certain other cellular proteins that might be resident in the cell membrane at the time. In the Tü bingen experitwo membranes should be independent of whether the gp120/gp41 partners are on the viral membrane or on ment, as the Rhabdoviral nucleoprotein core exits the cell, it "mistakenly" carries with it low levels of the corethe cell membrane. Simple binding by gp120/gp41 in a membrane of a target coreceptor complex, such as CD4 ceptors that Mebatsion and colleagues (1997) placed in the cell membrane. Since their engineered virus does and CXCR4, in another membrane should initiate the fusion event. Indeed, nearly a decade ago it was obnot have G protein to allow entry to target cells, the only way it can enter a target cell would be to use the served that as syncytia-inducing HIV-1 strains underwent lytic replication and viral burst from cells, cell coreceptors that "came along for the ride." As predicted, the viruses specifically infected cells that were expressmembranes could be observed to be undergoing "selffusion" with characteristic membrane blebbing and acing the HIV-1 gp120/gp41 envelope proteins on the cell surface but not cells that did not express gp120/gp41. companied cell-cell fusion. Therefore, it has been long understood that gp120/gp41 could be on membranes These viruses could only infect cells for a single round.
Although the Rhabdoviruses entered the gp120/gp41-might such viruses effect the health of a severely immunocompromised patient? What would happen if such a expressing cells, they possessed no ability to express any new envelope protein whatsoever and viral replicavirus were transferred accidentally by a treated HIV-1 patient to another individual, HIV-1 infected or not, who tion ceased with that cell, terminating the experiment. The authors later enhanced the efficiency of singlehas not agreed to receive the therapy? Would one ever treat a pregnant patient? Is it possible to introduce "govround infection by concentrating in the viral membrane the chemokine receptor and CD4 by further engineering ernor" controls into such a virus to limit its spread and effect beyond the cells intended? them to contain those features of the G protein tail that facilitates G protein assembly into mature Rhabies virus Thus, even if not readily transferred from one person to another, any use of a self-replicating "drug" requires particles. The results of the report are important not only for the specificity of the targetting effect itself. The data levels of governmental approval that should go to the highest levels of ethical and medical review. There are also demonstrates that understanding viral assembly processes can provide directions by which one might far more questions that need to be asked beyond those addressed in the space here. Given this, however, the enhance the efficiency of the targeting process through concentrating the coreceptors into the engineered virus results do point in a number of fascinating directions and lead to obvious approaches that fall far short of the envelope.
The report by Schnell and colleagues (1997) took this a use of viruses themselves, opening therapeutic advances that can have near-term applications. step further by creating viruses that killed HIV-1-infected cells and then acted as self-replicating watchguards For instance, one could consider creating nonviral delivery devices, or packets, that have embedded in against further HIV-1 spread. These workers engineered a relative of the Rabies virus, VSV, by replacing its G their membranes coreceptor complexes that bind the different HIV-1 gp120/gp41 envelope variants. Within envelope protein with expression cassettes for CD4 and CXCR4. Thus, cells infected with such an engineered these devices (encased in synthetic membranes called liposomes) could be anti-HIV-1 drugs with a variety of virus express all the structural core proteins of VSV as well as the coreceptor pair CD4 and CXCR4. This propurposes. This would overcome previous difficulties with liposomes that arose from their lack of specificity vided an enhanced ability-an engineered virus that was not only capable of infecting and destroying a cell exand low efficiency of fusion, since coreceptor embedding incorporates a self-loaded specificity element and pressing HIV-1 envelope protein, but that also propagates through the culture carrying a new determinant fusion trigger. One could deliver drugs this way that kill HIV-1-infected cells or in some other manner inhibit of infection (CD4 and CXCR4), continuouslly killing any cells that might dare to express HIV-1 envelope protein.
replication of HIV-1. This has merit since many anti-HIV-1 drugs have serious side effects that can debilitate In one fascinating experiment, the authors show that a T cell culture infected with both HIV-1 and engineered cells that are not infected. Thus, the broad concept of selective toxicity again comes into play. One can Rhabdoviral particles rapidly converted to a culture of cells that dropped infectious HIV-1 levels nearly 1000-selectively deliver a drug only to those cells that have HIV-1, thereby avoiding many of the nastier side effects fold. Minor low-level "bursts" of HIV-1 replication that occurred over a 30-day period were apparently rapidly of the drug. It is even possible to create simple nonviral liposome suppressed by remaining engineered virus in the culture. Presumably, in some rare cells HIV-1 had not activated devices of this nature that incorporate several HIV-1 chemokine receptors along with CD4 to target all cell gp120/gp41 to an extent that allowed detection by the engineered VSV virus. However, when HIV-1 "fully actitypes infected expressing gp120/gp41 (one must be careful to consider uninfected cells that might somehow vated" in those cells, they presumably were detected and destroyed by the engineered VSV. It will be imporacquire gp120/gp41 adventitiously). Cell-free HIV-1 particles in solution could also be targeted and infused with tant at some later date to determine, and lower, the level of gp120/gp41 required to initiate binding coreceptor toxins, essentially delivering an HIV-1 "disinfectant" that disables its ability to even enter a cell or replicate there. expressing engineered particles to catch HIV-1 as early in its burst phase as possible.
Could blood supply products be made more safe by such cleansing agents? Could a specially engineered Prospects for Viraceuticals: Merging the Concepts of Viral Biology with coreceptor complex, delivered as free protein, be used to bind to free or budding virus, block its ability to enter Pharmaceutical Design? As important as these results are in terms of specifically new cells, or trigger its natural clearance by the immune system without the use of any drugs or toxins at all? targeting HIV-1-infected cells, is the approach ready for use in patients? Are we ready to use one group Such approaches could avoid the issues of a self-replicating virus as drug and might gain rapid approval in of replication-competent viral pathogens to fight the ravages of another? Are we even ready to use singlemedical and ethical circles for more immediate application in patients. Since so many different guns can now round delivery of replication-incompetent virus to kill HIV-1-infected cells? The answer at this early juncture be aimed-at a target that HIV-1 cannot readily mutate from view-the possibilities raised are exciting indeed. is clearly no, that more work needs to be done to understand the implications of the results. For instance, it is Summary We are a step closer to goals of creating engineered critical to consider the multiple potential outcomes of introducing a novel replicating virus into the environviruses and nonviral devices for selective delivery of pharmaceuticals to HIV-1-infected cells. The viral apment, even if such a virus is intended only for the "environment" of a patient and has a therapeutic intent. How proaches must still be considered experimental and should be given significant review before their use, if ever, in humans. However, they point to a variety of nonviral applications with the prospect of safely delivering drug candidates to HIV-1-infected cells or cellfree HIV-1. Since others have previously designed viruses that preferentially replicate in cancer cells or have created targeting approaches for other drugs (Bischoff et al., 1996) , the merging of the fields of pharmaceuticals with delivery approaches gleaned from studying viral entry is fertile ground for advances against many other diseases. Future applications could involve evolving drugs or targeting specificities using viruses in the test tube, by applying straightforward genetic principles, that can specifically act against a given disease process and then use nonviral derivatives, or safe viral approaches, for use in humans. The insights provided by the Yale and Tü bingen groups point to methods of enhancing drug specificities that would be well-appreciated by classical pharmacologists and provide a powerful set of specific therapeutics. It now remains to be seen whether we are up to the challenge of appropriately administering and taking advantage of them.
